
    
      Post-approval study designed to collect primarily safety data on the US FDA-cleared product,
      t:slim X2 insulin pump with Control-IQ technology (Control-IQ system), by assessing the rate
      of severe hypoglycemia (SH) and diabetic ketoacidosis (DKA) during the first 12 months of
      use. Secondary endpoints assessing the effectiveness of this product in real-world use by
      assessing the impact on patients' glycemic outcomes and user experience will also be
      collected. The Control-IQ system will be used as intended and in accordance with FDA-approved
      labeling.
    
  